119 results on '"Sharifi, Mehran"'
Search Results
2. Melatonin affects the expression of microRNA-21: A mini-review of current evidence
- Author
-
Rafiyian, Mahdi, Gouyandeh, Farzaneh, Saati, Maryam, Davoodvandi, Amirhossein, Rasooli Manesh, Sayyed Mehdi, Asemi, Reza, Sharifi, Mehran, and Asemi, Zatollah
- Published
- 2024
- Full Text
- View/download PDF
3. Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients
- Author
-
Nasri, Elahe, Vaezi, Afsane, Falahatinejad, Mahsa, Rizi, Mahnaz Hosseini, Sharifi, Mehran, Sadeghi, Somayeh, Ataei, Behrooz, Mirhendi, Hossein, and Fakhim, Hamed
- Published
- 2023
- Full Text
- View/download PDF
4. Electromagnetic effects on the solidification of a metallic alloy droplet impacting onto a surface
- Author
-
Sharifi, Mehran and Amani, Ehsan
- Published
- 2024
- Full Text
- View/download PDF
5. Modulation of long non-coding RNAs by resveratrol as a potential therapeutic approach in cancer: A comprehensive review
- Author
-
Asemi, Reza, Rajabpoor Nikoo, Nesa, Asemi, Zatollah, Shafabakhsh, Rana, Hajijafari, Mohammad, Sharifi, Mehran, Homayoonfal, Mina, Davoodvandi, Amirhossein, and Hakamifard, Atousa
- Published
- 2023
- Full Text
- View/download PDF
6. Therapeutic effects of melatonin on endometriosis, targeting molecular pathways: Current knowledge and future perspective
- Author
-
Sharifi, Mehran, Rajabpoor Nikoo, Nesa, Badehnoosh, Bita, Shafabakhsh, Rana, Asemi, Reza, Reiter, Russel J., and Asemi, Zatollah
- Published
- 2023
- Full Text
- View/download PDF
7. The molecular perspective on the development of melanoma and genome engineering of T-cells in targeting therapy
- Author
-
Hajibabaie, Fatemeh, Abedpoor, Navid, Haghjooy Javanmard, Shaghayegh, Hasan, Anwarul, Sharifi, Mehran, Rahimmanesh, Ilnaz, Shariati, Laleh, and Makvandi, Pooyan
- Published
- 2023
- Full Text
- View/download PDF
8. Oncology Nurses' Needs Respecting Healthy Work Environment in Iran: A Descriptive Exploratory Study
- Author
-
Soheili, Mozhgan, Taleghani, Fariba, Jokar, Fariba, Eghbali-Babadi, Maryam, and Sharifi, Mehran
- Published
- 2021
- Full Text
- View/download PDF
9. The therapeutic effects of berberine for gastrointestinal cancers.
- Author
-
Davoodvandi, Amirhossein, Sadeghi, Sahand, Alavi, Seyed Mohammad Amin, Alavi, Seyedeh Shaghayegh, Jafari, Ameneh, Khan, Haroon, Aschner, Michael, Mirzaei, Hamed, Sharifi, Mehran, and Asemi, Zatollah
- Subjects
GASTROINTESTINAL cancer ,BERBERINE ,ANTINEOPLASTIC combined chemotherapy protocols ,DRUG therapy ,PANCREATIC cancer - Abstract
Cancer is one of the most serious human health issues. Drug therapy is the major common way to treat cancer. There is a growing interest in using natural compounds to overcome drug resistance, adverse reactions, and target specificity of certain types of drugs that may affect several targets with fewer side effects and be beneficial against various types of cancer. In this regard, the use of herbal medicines alone or in combination with the main anticancer drugs is commonly available. Berberine (BBR), a nature‐driven phytochemical component, is a well‐known nutraceutical due to its wide variety of pharmacological activities, including antioxidant, anti‐inflammatory, antibacterial, antifungal, antiparasitic, antidiabetic, antihypertensive, and hypolipidemic. In addition, BBR exerts anticancer activities. In present article, we summarized the information available on the therapeutic effects of BBR and its mechanisms on five types of the most prevalent gastrointestinal cancers, including esophageal, gastric, colorectal, hepatocarcinoma, and pancreatic cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study.
- Author
-
Soltani, Mohammad, Sharifi, Mohammad Jafar, Khalilian, Parvin, Sharifi, Mehran, Nematollahi, Pardis, Shapourian, Hooriyeh, and Hakemi, Mazdak Ganjalikhani
- Subjects
MYELODYSPLASTIC syndromes ,GENE expression ,SOMATIC mutation ,DYSPLASIA ,PYROPTOSIS ,HEMATOLOGIC malignancies - Abstract
Background: Myelodysplastic syndromes (MDS) are determined by ineffective hematopoiesis and bone marrow cytological dysplasia with somatic gene mutations and chromosomal abnormalities. Accumulating evidence has revealed the pivotal role of NLRP3 inflammasome activation and pyroptotic cell death in the pathogenesis of MDS. Although MDS can be diagnosed with a variety of morphologic and cytogenetic tests, most of these tests have limitations or problems in practice. Materials and Methods: In the present study, we evaluated the expression of genes that form the inflammasome (NLRP3, ASC, and CASP1) in bone marrow specimens of MDS patients and compared the results with those of other leukemias to evaluate their diagnostic value for MDS. Primary samples of this observational cohort study were collected from aspiration samples of patients with myelodysplastic syndromes (27 cases) and patients with non-myelodysplastic syndrome hematological cancers (45 cases). After RNA extraction and c.DNA synthesis, candidate transcripts and housekeeping transcripts were measured by real-time PCR method (SYBER Green assay). Using Kruskal-Wallis the relative gene expressions were compared and differences with p value less than 0.05 were considered as significant. Discrimination capability, cut-off, and area under curve (AUC) of all markers were analyzed with recessive operation curve (ROC) analysis. Results: We found that Caspase-1 and ASC genes expressed at more levels in MDS specimens compared to non-MDS hematological malignancies. A relative average expression of 10.22 with a p-value of 0.001 and 1.86 with p=0.019 was detected for Caspase-1 and ASC, respectively. ROC curve analysis shows an AUC of 0.739 with p=0.0001 for Caspase-1 and an AUC of 0.665 with p=0.0139 for ASC to MDS discrimination. Conclusion: Our results show that Caspase-1 and ASC gene expression levels can be used as potential biomarkers for MDS diagnosis. Prospective studies with large sample numbers are suggested. [ABSTRACT FROM AUTHOR]
- Published
- 2024
11. Chitosan as possible inhibitory agents and delivery systems in leukemia
- Author
-
Zivarpour, Parinaz, Hallajzadeh, Jamal, Asemi, Zatollah, Sadoughi, Fatemeh, and Sharifi, Mehran
- Published
- 2021
- Full Text
- View/download PDF
12. The role of dietary polyphenols in alternating DNA methylation in cancer.
- Author
-
Qadir Nanakali, Nadir Mustafa, Maleki Dana, Parisa, Sadoughi, Fatemeh, Asemi, Zatollah, Sharifi, Mehran, Asemi, Reza, and Yousefi, Bahman
- Subjects
DNA methylation ,QUERCETIN ,EPIGALLOCATECHIN gallate ,TUMOR suppressor genes ,POLYPHENOLS ,NATURAL products ,DNA methyltransferases ,NON-coding RNA - Abstract
Natural products such as curcumin, quercetin, and resveratrol have been shown to have antitumor effectsand several studies have examined their role in treating cancer, either alone or in combination with other chemotherapeutic drugs. These compounds are capable of affecting different cancer-related mechanisms, such as proliferation, inflammation, invasion, and metastasis. Along with all of the benefits of these agents, affecting epigenetic processes is one of the most important aspects of their impact. Epigenetic modifications can be categorized into three main processes that include DNA methylation, histone modification, and regulation of small non-coding RNAs. Therefore, targeting DNA methylation can be used as a cancer treatment strategy by identifying or developing methylation modulators. Herein, we take a look into the studies investigating the role of natural products (e.g. curcumin, resveratrol, epigallocatechin gallate (EGCG), and quercetin) in alternating the DNA methylation status of various cancer cells. We discuss how these compounds reduce the expression of enzymes mediating the methylation of tumor suppressor genes and thereby, increasing the expression of tumor suppressors while reactivating antitumor signaling pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Potential Drug Interactions in Terminally-Ill Cancer Patients, a Report from the Middle East.
- Author
-
Mahzoni, Hamed, Naghsh, Erfan, Sharifi, Mehran, Moghaddas, Ayda, Momenzadeh, Mahnaz, and Moghaddas, Azadeh
- Subjects
CANCER patient psychology ,CROSS-sectional method ,QUETIAPINE ,OXYCODONE ,DRUG interactions ,DESCRIPTIVE statistics ,RESEARCH funding ,PSYCHOLOGY of the terminally ill ,DATA analysis software ,TUMORS ,SERTRALINE ,DRUG toxicity - Abstract
This study aims to evaluate the epidemiology of potential drug interactions in terminally-ill cancer patients receiving exclusively supportive care. In this cross-sectional study, during a 6-month follow-up, we considered the medical record of terminally-ill cancer patients referred to palliative care at the cancer center in Isfahan, Iran. Potential drug-drug interactions (DDIs) were assessed by Lexi-Interact ver.1.1 online software. During the study period, 133 terminally-ill cancer patients were recruited. We detected 1678 DDIs with moderate or major severity levels. Among them, 330, 219, 32, 1075, and 51 interactions were categorized in B, C, D, and X drug interactions categories, respectively. One hundred and twenty-two patients (91.73%) encountered at least one potential drug-drug interaction during the end of life care. Mechanistically, most drug-drug interactions (64.5%) were pharmacodynamics. The most frequent pharmacological class of drugs responsible for DDIs were quetiapine (91 cases), oxycodone (87 cases), and sertraline (55 cases). Interaction between oxycodone and sertraline was found to be in the top 10 detected DDIs (13.7%). Our results showed that potentially moderate or major drug-drug interactions often occur among terminally-ill cancer patients and the clinical significance of DDIs should be considered meticulously in the palliative care cancer setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Curcumin supplementation prevents cisplatin-induced nephrotoxicity: a randomized, double-blinded, and placebo-controlled trial.
- Author
-
Mehrab, Hasan, Sharifi, Mehran, Akhavan, Ali, Aarabi, Mohammad-Hosein, Mansourian, Marjan, Mosavi, Elaheh, and Moghaddas, Azadeh
- Subjects
- *
CURCUMIN , *LIPOCALIN-2 , *POTASSIUM , *NEPHROTOXICOLOGY , *GLOMERULAR filtration rate , *DIETARY supplements , *DEMOGRAPHIC characteristics - Abstract
Background and purpose: Cisplatin-induced nephrotoxicity (CIN) remains the most prevailing unfavorable influence and may affect its clinical usage. This study sought to explore the possible impacts of curcumin on preventing CIN in human subjects. Clinical design: The investigation was a placebo-controlled, double-blinded, randomized clinical trial conducted on 82 patients receiving nano-curcumin (80 mg twice daily for five days) or an identical placebo with standard nephroprotective modalities against CIN. Data was gathered on patients' demographics, blood, urinary nitrogen, creatinine (Cr) levels, urinary electrolytes, and urine neutrophil gelatinase-associated lipocalin (NGAL) levels in treatment and placebo groups, 24 h and five days after initiating the administration of cisplatin. Findings/Results: Both investigation groups were alike considering the demographic characteristics and clinical baseline data. Curcumin administration led to a significant improvement in blood-urine nitrogen (BUN). BUN, Cr, glomerular filtration rate (GFR), and the ratio of NGAL-to-Cr considerably altered during the follow-up periods. However, the further alterations in other indices, including urinary sodium, potassium, magnesium, NGAL values, and potassium-to-Cr ratio were not statistically noteworthy. The significant differences in the NGAL-to-Cr ratio between the two groups may indicate the potential protective impact of curcumin supplementation against tubular toxicity. Curcumin management was safe and well-accepted; only insignificant gastrointestinal side effects were reported. Conclusion and implications: Curcumin supplementation may have the potential to alleviate CIN and urinary electrolyte wasting in cancer patients. Future research investigating the effects of a longer duration of follow-up, a larger participant pool, and a higher dosage of curcumin are recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer
- Author
-
Hallajzadeh, Jamal, Maleki Dana, Parisa, Mobini, Moein, Asemi, Zatollah, Mansournia, Mohammad Ali, Sharifi, Mehran, and Yousefi, Bahman
- Published
- 2020
- Full Text
- View/download PDF
16. The Effect of Bortezomib Regimen on Multiple Myeloma Patients Infected with COVID-19.
- Author
-
Rezaeian, Zahra, Abedini, Fatemeh, Arabzadeh, Saeedeh, Farzan, Maryam, Sharifi, Mehran, and Manteghinejad, Amirreza
- Subjects
MULTIPLE myeloma diagnosis ,COVID-19 ,CONFIDENCE intervals ,CANCER chemotherapy ,IMMUNE system ,RETROSPECTIVE studies ,BORTEZOMIB ,HEMATOLOGIC malignancies ,DESCRIPTIVE statistics ,RESEARCH funding ,MULTIPLE myeloma ,SARS virus ,STATISTICAL models ,LONGITUDINAL method ,PHARMACODYNAMICS ,DISEASE complications - Abstract
Background: Patients with multiple myeloma (MM) have compromised immune systems due to the nature of the malignancy and anticancer treatments. This study aims to report the effects of Bortezomib-containing chemotherapy regimens on the severity and mortality of MM patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Method: This retrospective cohort study enrolled MM patients presenting with coronavirus disease 2019 (COVID-19) infection referred to Omid Hospital. Patients were divided into two groups based on whether they received any chemotherapy regimens containing Bortezomib within the last 90 days of admission or not. Clinical and laboratory characteristics, severity, and outcomes of both groups were reported and compared. Results: Among 48 patients with MM diagnosed with COVID-19 (63% male; median age 66), 33 received chemotherapy. The most common symptoms were fever, cough, and dyspnea, and there was no significant difference between the groups. Only D-dimer had a significant difference in laboratory tests (P = 0.03) and was higher in the chemotherapy group. There was no significant relationship between chemotherapy and severity (risk ratio (RR) = 1.17; 95% confidence interval (CI): 0.37 to 3.71; P = 0.79) or chemotherapy and mortality (RR = 1.00; 95% CI: 0.39 to 2.61; P = 0.99), even after adjusting for baseline C-reactive protein and white blood cell counts. Conclusion: Our study showed that receiving Bortezomib-containing chemotherapy regimens did not worsen the symptoms and prognosis of MM patients infected with COVID-19. However, further studies with larger sample sizes and longer follow-up times are needed to provide better evidence on this subject. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Melatonin and non-small cell lung cancer: new insights into signaling pathways
- Author
-
Pourhanifeh, Mohammad Hossein, Sharifi, Mehran, Reiter, Russel J., Davoodabadi, Abdoulhossein, and Asemi, Zatollah
- Published
- 2019
- Full Text
- View/download PDF
18. Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia.
- Author
-
Rahmati, Atefe, Mafi, Alireza, Soleymani, Firooze, Aghdam, Zahra Babaei, Masihipour, Niloufar, Ghezelbash, Behrooz, Asemi, Reza, Aschner, Michael, Vakili, Omid, Homayoonfal, Mina, Asemi, Zatollah, Sharifi, Mehran, Azadi, Abbas, Mirzaei, Hamed, and Aghadavod, Esmat
- Subjects
ACUTE myeloid leukemia ,CIRCULAR RNA ,HEMATOLOGIC malignancies ,NON-coding RNA ,RNA sequencing ,PRELEUKEMIA - Abstract
Acute myeloid leukemia (AML) is an aggressive hematological malignancy and affected patients have poor overall survival (OS) rates. Circular RNAs (circRNAs) are a novel class of non-coding RNAs (ncRNAs) with a unique loop structure. In recent years, with the development of high-throughput RNA sequencing, many circRNAs have been identified exhibiting either up-regulation or downregulation in AML patients compared with healthy controls. Recent studies have reported that circRNAs regulate leukemia cell proliferation, stemness, and apoptosis, both positively and negatively. Additionally, circRNAs could be promising biomarkers and therapeutic targets in AML. In this study, we present a comprehensive review of the regulatory roles and potentials of a number of dysregulated circRNAs in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Futile Medication in Palliative Cancer Patients; a Report from the Middle East.
- Author
-
Mahzoni, Hamed, Sharifi, Mehran, and Moghaddas, Azadeh
- Subjects
- *
TERMINALLY ill , *CROSS-sectional method , *MULTIVARIATE analysis , *CANCER patients , *RESEARCH funding , *FUTILE medical care , *LOGISTIC regression analysis , *DATA analysis software , *PALLIATIVE treatment , *LONGITUDINAL method - Abstract
Background: Palliative cancer patients suffer from a condition which needs to take many medications for supportive care and comorbid illnesses management. Therefore, they are at risk of drug-rated problems, such as futile medications. We aimed to discover the futile medication occurrence and identification as well as medication futility associated predictor factors. Method: In a prospective cross-sectional study, we included patients with advanced/incurable malignancies admitted to Ala palliative clinic, a charity clinic affiliated to Omid Hospital in Isfahan, Iran, between June 2018 and April 2019. To identify the use of fruitless medicine towards the end of life, we conducted a thorough analysis of the demographic information and prescription lists of terminally ill patients. The phrase "futile drugs" refers to those that are superfluous or redundant, have no significant benefits in terms of illness symptom management or survival time extension, or have a long-term chronic usage. Results: From 133 involved patients, 114 (85.7%) were considered to use at least one futile medication (including only administration of unnecessary medications (70%) or both unnecessary and duplicate medication (30%). 35 patients were encountered with 48 medication duplications of the different pharmacological class of medications mostly opioids (33%). According to multivariate logistic regression analysis, the number of drugs and the average time to death were related with the prevalence of medication futility. Conclusion: Palliative cancer patients were exposed to taking futile medications. More different prospective studies are warranted to evaluate the clinical and economic impact of futile medication use in oncology practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Performance challenges in a newly established clean room at Omid Hospital, Isfahan, Iran: A descriptive study.
- Author
-
Vaez, Mehrnaz, Sharifi, Mehran, Karimi, Sahar, and Moghaddas, Azadeh
- Published
- 2023
- Full Text
- View/download PDF
21. The Efficacy and Safety of Captopril in Preventing Capecitabine-induced Hand-foot Syndrome: A Randomized Double-blinded Placebo-controlled Clinical Trial.
- Author
-
Roayaei, Mahnaz, Nazeminezhad, Nooshin, Najafizade, Nadia, and Sharifi, Mehran
- Subjects
HAND-foot syndrome ,DRUG efficacy ,COLORECTAL cancer ,RANDOMIZED controlled trials ,COMPARATIVE studies ,CAPTOPRIL ,DESCRIPTIVE statistics ,STATISTICAL sampling ,TUMOR markers ,PATIENT safety - Abstract
Background: Hand-foot syndrome (HFS) is a prevalent skin reaction to cytotoxic systemic therapy, mainly Capecitabine. The present study aimed to determine etiologies of HFS in addition to its prevention in colorectal cancer patients with Capecitabine-containing chemotherapy regimen. Method: In this randomized double-blinded study, we recruited 66 eligible patients. The first 33 patients received 25 mg captopril twice daily, while the other 33 were given two placebo tablets. Results: All the patients were assessable for safety and efficacy. Captopril demonstrated a favorable safety profile. The participants in the two groups did not have any significant differences in terms of the median age and the level of hemoglobin (P = 0.45, P = 0.06, respectively). However, the CEA tumor marker was significantly higher in those with HFS (P < 0.05). The incidence of HFS in men and women were 8 (18.6%) and 3 (13%) cases, respectively, and the patients' sex did not affect the incidence of this syndrome (P = 0.73). Furthermore, according to the stage of colorectal cancer, the difference between the two groups was significant (P < 0.05). Meanwhile, there were no significant differences concerning the grade of colorectal cancer (P = 0.2). Conclusion: The results herein revealed that administration of captopril in colorectal cancer patients with Capecitabine-containing chemotherapy regimen reduced the symptoms and incidence of HFS. On the other hand, CEA tumor marker and the stage of colorectal cancer were in correlation with incidence of HFS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. A systematic review evaluating the efficacy of autologous hematopoietic transplantation for diffuse large B cell lymphoma-type Richter syndrome.
- Author
-
Sharifi, Mehran, Farajzadegan, Ziba, and Jouzdani, Saeid Rezaei
- Abstract
Background: Chronic lymphocytic leukemia (CLL) can transform into fast growing lymphoma for diffuse large B-cell lymphoma (DLBCL) called Richter's syndrome (RS), which is commonly related to an existence of large B-cells with equal or larger size than macrophage nuclei or more than twice those of normal lymphocyte. We conducted a systematic review of the existing literature to assess the clinical efficacy of auto-HCT for patients with RS. Methods: We searched 4 main databases; EMBASE, Google Scholar, Scopus, PubMed and Web of Science and was done on December 26, 2021. All analyses in this study were performed by Stata software and this review was reported in accordance with PRISMA 2020. Results: Data was extracted from 4 articles; the total number of patients was reported to be 110. Based on the meta-analysis findings, pooled overall survival rate was 56.36% (95%CI= (46.98–65.31). In figure 2, the forest plot of combined results is shown. Conclusion: Despite the use of common treatment regimens such as chemo immunotherapy and the availability of novel therapies including B-cell receptor inhibitors and rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone (CHOP-R) regimen, the status of disease progression and recovery in RS cases is still not strong enough. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east.
- Author
-
Farrokhi, Pegah, Sadeghi, Alireza, Sharifi, Mehran, Riechelmann, Rachel, and Moghaddas, Azadeh
- Subjects
ANTINEOPLASTIC combined chemotherapy protocols ,STOMACH cancer ,EPIRUBICIN ,CANCER patients ,CANCER chemotherapy ,OXALIPLATIN ,SURGERY safety measures ,CISPLATIN - Abstract
Background and purpose: This study aimed to compare the efficacy and toxicity of perioperative chemotherapy regimens including epirubicin, cisplatin, 5-fluorouracil (ECF), docetaxel, cisplatin, 5-fluorouracil (DCF), leucovorin, 5-fluorouracil, oxaliplatin (FOLFOX), and 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) to identify the most effective chemotherapy regimen with less toxicity. Experimental approach: This retrospective cohort study (2014-2021) was based on 152 eligible resectable gastric cancer patients who had received one of the perioperative mentioned chemotherapy regimens and followed for at least two years. The primary endpoint of this study was overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and R0 resection. Findings / Results: Of included patients, 21%, 33.7%, 24.3%, and 21% had received ECF, DCF, FOLFOX and FLOT, respectively. After the median 30-month follow-ups, OS was higher with the FLOT regimen in comparison with other regimens (hazard ratio = 0. 276). The median OS of the FLOT regimen was 39 months. Besides, the median OS was 28, 25, and 21 months for DCF, FOLOFX, and ECF regimens, respectively. Moreover, a median PFS of 24, 18, 17, and 14 months was observed for FLOT, DCF, FOLFOX, and ECF regimens, respectively (Log-rank < 0.001). FLOT regimen showed 84. 4% ORR which was notably higher than other groups. Conclusions and implications: For resectable gastric cancer patients, the perioperative FLOT regimen led to a significant improvement in patients' OS and PFS versus ECF, DCF, and FOLFOX regimens. As such, the FLOT regimen could be considered the optimal option for managing resectable gastric cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Interlaboratory comparability of serum cotinine measurements at smoker and nonsmoker concentration levels : A round-robin study
- Author
-
Bernert, John T., Jacob, Peyton, Holiday, David B., Benowitz, Neal L., Sosnoff, Connie S., Doig, Mira V., Feyerabend, Colin, Aldous, Kenneth M., Sharifi, Mehran, Kellogg, Mark D., and Langman, Loralie J.
- Published
- 2009
25. COVID-19 Breakthrough Infections Among Patients with Cancer Receiving Sinopharm BBIBP-CorV Vaccine.
- Author
-
Manteghinejad, Amirreza, Arabzadeh, Saeedeh, Rezaian, Zahra, Sharifi, Mehran, and Javanmard, Shaghayegh Haghjooy
- Subjects
BREAKTHROUGH infections ,REPORTING of diseases ,COVID-19 ,COVID-19 vaccines ,CANCER chemotherapy ,RETROSPECTIVE studies ,ACQUISITION of data ,CANCER patients ,MEDICAL records ,DESCRIPTIVE statistics ,HEMATOLOGIC malignancies ,TUMORS ,COVID-19 testing ,POLYMERASE chain reaction ,DISEASE complications - Abstract
Background: Patients with cancer are at an increased risk of mortality from COVID-19 infection. So, they are prioritized for vaccination. However, there is limited data about the immunogenicity, safety, and effectiveness of inactivated vaccines in preventing COVID-19 infection, hospitalization, and mortality in patients with cancer. Objectives: This study aimed to report the clinical characteristics of patients who had a positive PCR test after being fully vaccinated with the Sinopharm BBIBP-CorV Vaccine. Methods: In this retrospective study, the data of patients with cancer were extracted from the electronic health records of a cancer center in Isfahan, Iran. All COVID-19 data from Isfahan province also was collected by Isfahan COVID-19 Registry (I-CORE). We described the clinical characteristics of patients with cancer who have a positive test more than 14 days after the second dose. Results: Two hundred twenty-two patients with cancer had at least one positive PCR test after the start of the COVID-19 vaccination. Of these, 9 (4.1%) breakthrough infections have occurred. Six (67%) of them had hematological malignancies. Six (67%) were hospitalized and 3 (33%) patients died. Two of them had recent chemotherapy and have hematological malignancies. Conclusions: Vaccination is a good way to protect the population from COVID-19 complications and mortality, but it should be considered that fully-vaccinated patients with cancer are at risk of severe outcomes. Nevertheless, prioritizing cancer patients, especially those with hematological malignancies, or receiving chemotherapies for booster vaccines and studying the effectiveness of each COVID-19 vaccine for patients with cancer should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The Effects of Sterol-Related Signaling Pathways on Glioma.
- Author
-
Eslahi, Masoumeh, Maleki Dana, Parisa, Sadoughi, Fatemeh, Hallajzadeh, Jamal, Asemi, Zatollah, Sharifi, Mehran, Mansournia, Mohammad Ali, and Yousefi, Bahman
- Subjects
GLIOMA treatment ,STEROLS ,EPIDERMAL growth factor receptors ,GLIOMAS ,CELLULAR signal transduction ,DISEASE risk factors - Abstract
Gliomas are considered as one of the important brain tumors in adults due to their impact on life quality and cognitive functions. Current methods that are used for treating glioma are not satisfying enough. Understanding cellular and molecular events underlying its pathogenesis and progression may lead to the discovery of novel therapeutic approaches. Sterols are a subtype of steroids and are essential for the physiologic functions of eukaryotic cells. Sterols can be produced by protozoans and microheterotrophs. Moreover, they are found in some natural sources, such as plants, animals, fungi, microalgae, and yeasts. Besides the roles of sterols in physiologic processes, studies have shown that they are involved in pathologic processes, including tumorigenesis and tumor progression. As investigations have revealed, sterol-related signaling pathways are involved in glioma and targeting them may result in new therapeutic options for patients. Thus, we summarized some of the sterol-related signaling pathways in glioma and how they can be associated with other signaling pathways, including EGFR/PI3K/Akt/mTOR, P53, and retinoblastoma protein. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Intestinal parasitic infections in renal transplant recipients
- Author
-
Azami, Mehdi, Sharifi, Mehran, Hossein Hejazi, Sayed, and Tazhibi, Mehdi
- Published
- 2010
28. Melatonin in the prevention of cisplatin-induced acute nephrotoxicity: a randomized, controlled clinical trial.
- Author
-
Karvan, Sara, Sadeghi, Alireza, Farrokhi, Pegah, Nekouee, Amirabbass, Sharifi, Mehran, and Moghaddas, Azadeh
- Subjects
LIPOCALIN-2 ,CISPLATIN ,MELATONIN ,CLINICAL trials ,NEPHROTOXICOLOGY ,RANDOMIZED controlled trials - Abstract
Background and purpose: Cisplatin-induced nephrotoxicity (CisIN) remains the most dose-limiting adverse effect of its clinical use. The protective effects of melatonin on CisIN have been addressed in several non- clinical and animal studies. This study aimed at investigating the potential effects of melatonin on the prevention of CisIN in human. Experimental approach: Our study was a randomized controlled clinical trial, performed on 66 eligible patients in two groups of melatonin or control (no intervention). Melatonin was administrated daily at a dose of 20 mg for 5 days to the patients receiving cisplatin-containing regimens along with the standard protocol of CisIN prevention. Patient demographic information, blood and urinary indices of nitrogen, creatinine, and electrolytes such as sodium, potassium, magnesium as well as neutrophil gelatinase-associated lipocalin were measured in both groups at the baseline, 24 h and five days after melatonin administration. Findings/Results: Cisplatin administration resulted in significant magnesium and potassium loss in patients with cancer. In comparison with the control group, the prevalence of acute renal injury and the rate of urinary magnesium and potassium loss improved with melatonin administration; however, the results were not statistically significant. Tolerable side effects such as daytime drowsiness, nausea, and vomiting were reported in the melatonin group. Conclusion and implications: Although pretreatment with melatonin led to amelioration in urinary electrolyte loss due to CisIN, it failed to show a positive result on acute renal injury prevention. Future well-designed studies with a longer duration of follow-up, larger sample sizes, and higher doses of melatonin are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Quantitative method for the analysis of tobacco-specific nitrosamines in cigarette tobacco and mainstream cigarette smoke by use of isotope dilution liquid chromatography tandem mass spectrometry
- Author
-
Wu, Jingcun, Joza, Peter, Sharifi, Mehran, Rickert, William S., and Lauterbach, John H.
- Subjects
Nitrosoamines -- Measurement ,Nitrosoamines -- Properties ,Mass spectrometry -- Methods ,Liquid chromatography -- Methods ,Tobacco products -- Composition ,Chemistry, Analytic -- Quantitative ,Chemistry, Analytic -- Methods ,Chemistry - Abstract
An improved liquid chromatography tandem mass spectrometry (LC--MS/MS) method has been developed for the determination of tobacco specific nitrosamines (TSNA). It utilizes four stable isotope-labeled internal standards instead of two as reported by others. A separate internal standard for each analyte is required to minimize sample matrix effects on each analyte, which can lead to poor analyte recoveries and decreases in method accuracy and precision if only one or two of the internal standards are used, especially for complex sample matrixes and when no sample cleanup steps are performed as in this study. In addition, two ion-transition pairs (instead of one) are used for each analyte for the confirmation and quantification, further enhancing the method's accuracy and robustness. These improvements have led to a new LC-MS/MS method that is faster, more sensitive, and selective than the traditional methods and more accurate and robust than the published LC--MS/MS methods. The linear range of the method was from 0.2 to 250 ng/mL with a limit of detection of each TSNA varied from 0.027 to 0.049 ng/mL. Good correlations between the results obtained by the new method and the traditional method were observed for the samples studied.
- Published
- 2008
30. Utility Values in Colorectal Cancer Patients Treated with Chemotherapy.
- Author
-
Atfannezhad, Majid, Sharifi, Mehran, Madadizadeh, Farzan, and Ameri, Hosein
- Subjects
- *
PAIN , *CANCER chemotherapy , *COLORECTAL cancer , *CANCER patients , *INCOME , *SOCIOECONOMIC factors , *TUMOR classification , *AGING , *ANXIETY , *COMORBIDITY - Abstract
Calculating utility values in colorectal cancer (CRC) patients under chemotherapy treatment is important for studies of economic evaluations. The EQ-5D-5L and composite time trade-off (cTTO) were used to calculate utility values in 105 patients with CRC in Iran. The mean EQ-5D-5L index and cTTO values were 0.45 ± 0.03 and 0.51 ± 0.02, respectively. Anxiety and pain were the most common problems reported by the patients. The BetaMix showed that lower mean utility values were significantly associated with females, aging, a low level of income, a greater number of comorbidities, and an advanced stage of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Occupational stressors in oncology nurses: A qualitative descriptive study.
- Author
-
Soheili, Mozhgan, Taleghani, Fariba, Jokar, Fariba, Eghbali‐Babadi, Maryam, and Sharifi, Mehran
- Subjects
ONCOLOGY nursing ,OCCUPATIONAL achievement ,NURSES' attitudes ,JOB stress ,RESEARCH methodology ,INTERVIEWING ,WORK-life balance ,QUALITATIVE research ,CANCER patients ,DESCRIPTIVE statistics ,RESEARCH funding ,CONTENT analysis ,JUDGMENT sampling ,DATA analysis software - Abstract
Aim and objectives: The present study aims at exploring oncology nurses' perceptions regarding work‐related stressors. Background: Oncology nurses work in an environment with a high degree of stress, which can negatively affect their health. There is limited research on work‐related stressors from the oncology nurses' perspective. Design: Qualitative descriptive study. Methods: Fifty‐two oncology nurses were selected purposefully from eight cancer treatment centres in different cities of Iran. Data were collected through semi‐structured interviews and analysed using conventional content analysis. The COREQ checklist was used to document the report of the study. Results: The extracted contents were classified into four main categories. The first category involved personal ability with two subcategories (person‐job fit and psychological competencies). The second category included physical environment arrangements with two subcategories (physical working conditions and equipment and facilities). The third category involved psychosocial safety in the workplace with four subcategories (creating a safe work environment, overcoming the challenges of providing care to cancer patients, work/life balance and social recognition of the nursing status). The fourth category holds an organisational context with four subcategories (organisational support, interpersonal relations, justice at work and human resources). Conclusion: It is necessary to find measures attenuating work‐related stresses in oncology nurses. These measures should be in line with developing personal abilities in nurses and creating a safe environment in terms of optimising physical, psychosocial and organisational conditions. It is also important to develop programmes protecting the oncology nurses' occupational health. Relevance to clinical practice: The results of this study can help improve nursing work conditions, attenuate work‐related stresses in nurses and introduce efficient interventions reducing occupational stressors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Exploring the occupational health needs of oncology nurses: A qualitative study.
- Author
-
Soheili, Mozhgan, Jokar, Fariba, Eghbali-Babadi, Maryam, Sharifi, Mehran, and Taleghani, Fariba
- Published
- 2021
- Full Text
- View/download PDF
33. An inter-laboratory comparison of urinary 3-hydroxypropylmercapturic acid measurement demonstrates good reproducibility between laboratories
- Author
-
Bailey Brian, Sharifi Mehran, Newland Kirk, Scherer Gerhard, Errington Graham, Minet Emmanuel, McEwan Mike, and Cheung Francis
- Subjects
Medicine ,Biology (General) ,QH301-705.5 ,Science (General) ,Q1-390 - Abstract
Abstract Background Biomarkers have been used extensively in clinical studies to assess toxicant exposure in smokers and non-smokers and have recently been used in the evaluation of novel tobacco products. The urinary metabolite 3-HPMA, a metabolite of the major tobacco smoke toxicity contributor acrolein, is one example of a biomarker used to measure exposure to tobacco smoke. A number of laboratories have developed liquid chromatography with tandem mass spectrometry (LC-MS/MS) based methods to measure urinary 3-HPMA; however, it is unclear to what extent the data obtained by these different laboratories are comparable. Findings This report describes an inter-laboratory comparison carried out to evaluate the comparability of 3-HPMA measurement between four laboratories. A common set of spiked and authentic smoker and non-smoker urine samples were used. Each laboratory used their in-house LC-MS/MS method and a common internal standard. A comparison of the repeatability ('r'), reproducibility ('R'), and coefficient of variation for 3-HPMA demonstrated that within-laboratory variation was consistently lower than between-laboratory variation. The average inter-laboratory coefficient of variation was 7% for fortified urine samples and 16.2% for authentic urine samples. Together, this represents an inter-laboratory variation of 12.2%. Conclusion The results from this first inter-laboratory comparison for the measurement of 3-HPMA in urine demonstrate a reasonably good consensus between laboratories. However, some consistent measurement biases were still observed between laboratories, suggesting that additional work may be required to further reduce the inter-laboratory coefficient of variation.
- Published
- 2011
- Full Text
- View/download PDF
34. Integrin α6 β4 on Circulating Tumor Cells of Metastatic Breast Cancer Patients.
- Author
-
Sharifi, Mehran, Zarrin, Bahareh, Najafi, Majed Bahri, Hakimian, Mohamad Reza, Hosseini, Nastaran, Talebi, Kasra, and Javanmard, Shaghayegh Haghjooy
- Published
- 2021
- Full Text
- View/download PDF
35. Validation of a newly developed questionnaire regarding clinical history in patients with breast and colorectal cancers.
- Author
-
Vafaei, Zamaneh, Najafian, Jamshid, Shekarchizadeh, Masood, Mostafavi, Samaneh, Darakhshandeh, Ali, Khosravifarsani, Mohammadreza, Ashrafi, Farzaneh, Sharifi, Mehran, Mohammadifard, Noushin, Emami, Mohammad Hassan, Haghjooy-Javanmard, Shaghayegh, and Sarrafzadegan, Nizal
- Subjects
COLORECTAL cancer ,BREAST cancer ,INTRACLASS correlation ,TEST validity ,CRONBACH'S alpha - Abstract
BACKGROUND: Understanding the close interaction between the specialties of cardiology and oncology is necessary for early detection of cardiovascular disease (CVD) events in cancer patients. For the risk assessment of CVD in Breast and Colorectal Cancers (CIBC) study, in the current study we aimed to validate a questionnaire for the assessment of clinical history in patients with breast cancer and colorectal cancer (CRC). METHODS: We determined the content validity of the questionnaire using the 2 indexes of content validity ratio (CVR) and content validity index (CVI) to examine the specificity, simplicity, clarity, and transparency of the items. Content validity assessment was performed through a panel of experts including 2 oncologists, 5 cardiologists, 2 general practitioners, and 1 epidemiologist. The reliability of the questionnaire was estimated using Cronbach's alpha coefficient in 50 patients. Intraclass correlation coefficient (ICC) was used to examine the reproducibility of the questionnaire during 1 week. RESULTS: The CRC and breast cancer questionnaire were designed with 16 and 32 questions, respectively. To obtain acceptable CVR, 5 and 11 questions were removed from the CRC and breast cancer questionnaires, respectively. Cronbach's alpha was 0.70 in the breast cancer questionnaire and 0.94 in the CRC questionnaire. All questions had a CVI of higher than 80%. The ICC in the breast cancer questionnaire ranged between 0.71 and 0.96 and in CRC questionnaire ranged between 0.78 and 0.98. CONCLUSION: The validity and reliability of our newly developed questionnaire was desirable. The reliability of the breast cancer questions was acceptable and that of the CRC questions was excellent. Thus, thus questionnaire can be used in this group of patients regardless of whether the goal is cardiac care or not. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Circular RNAs: new genetic tools in melanoma.
- Author
-
Hallajzadeh, Jamal, Amirani, Elaheh, Mirzaei, Hamed, Shafabakhsh, Rana, Mirhashemi, Seyyed M, Sharifi, Mehran, Yousefi, Bahman, Mansournia, Mohammad A, and Asemi, Zatollah
- Published
- 2020
- Full Text
- View/download PDF
37. A Sensitive and Quantitative Isotope-Dilution LC-MS/MS Method for Analysis of Hydrazine in Tobacco Smoke.
- Author
-
Sharifi, Mehran, Donisa, Carmen, and Joza, Peter
- Subjects
- *
TOBACCO smoke , *SMOKING , *TANDEM mass spectrometry , *TOBACCO analysis , *PERMEATION tubes , *MENTHOL - Abstract
A new isotope dilution liquid chromatography/tandem mass spectrometric method was developed for the analysis of potential hydrazine present in tobacco smoke. The sample preparation was performed via an optimized derivatization method using an aqueous buffer:methanol solution of 2-nitrobenzaldehyde (10 g/L) used as a derivatizing agent. The mainstream smoke of cigarettes was passed through a glass fiber filter pad followed by a trapping solution containing an isotopically labeled 15N2-hydrazine used as internal standard. After smoking, the filter pad was extracted with the trapping solution and then incubated for 30 minutes at 35°C. An aliquot of the extract was centrifuged and the resultant hydrazone was quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS). The isotope dilution standard calibration curve demonstrated good linearity (R 2 > 0.999) from 0.079 to 248 ng/mL, with limits of quantification in mainstream smoke of 0.2 and 0.4 ng/cig for ISO and Canadian Intense smoking regimens, respectively. The method recovery was assessed using samples spiked with solutions of known amounts of hydrazine. The results showed good accuracy with recoveries ranging from 98 to 111%. Although there were no detectable levels of hydrazine in the reference cigarettes used in the validation (KR3R4F), the method precision was estimated to be ~10% based on the variability observed in the spiked samples. Trapping efficiencies were assessed using a hydrazine permeation tube providing a known amount of hydrazine vapor such that the distribution between the vapor phase and particulate phase of mainstream smoke could be determined. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Rational, Design and Preliminary Results of a Cohort Study on Breast and Colorectal Cancer to Develop a Risk Assessment Model to Predict Future Cardiovascular Events. "Cardio Vascular Events in Breast and Colorectal Cancers (CIBC) Study".
- Author
-
Heshmat-Ghahdarijani, Kiyan, Najafian, Jamshid, Vafaei, Zamaneh, Mostafavi, Samaneh, Mohammadifard, Noushin, Mansourian, Marjan, Ashrafi, Farzaneh, Sharifi, Mehran, Khosravifarsani, Mohammadreza, Darakhshandeh, Ali, Mohammad Hassan, Emami, Shaghayegh Haghjooy, Javanmard, and Sarrafzadegan, Nizal
- Abstract
Breast cancer (BC) and colorectal cancer (CRC) are among the most common cancers in Iran. We aimed to develop a risk assessment model to predict the development of cardiovascular events in these patients by performing a 5 year prospective cohort study on a newly diagnosed patients with BC or CRC before they receive any treatment. A multi-center prospective cohort study of 2700 newly diagnosed BC and CRC patients has been started in Iran since 2019 and will be continued until 2024. Demographics, socioeconomic status, life style behaviors, psychological characteristics and type of cancer treatments will be collected by standard questionnaires and blood pressure, obesity indices will be measured. Blood sampling, ECG, and echocardiography will be done in all patients at base line, 6 and 12 months, then at annual basis for five years. Incidence of heart failure, acute coronary syndrome, stroke and CVD related death are the primary outcome of this study. In this preliminary analysis, 70 patients with BC and 30 patients with CRC were enrolled in this study from April 2019 to November 2019. Mean age of BC and CRC patients was 48 ± 10.5 and 61 ± 13.2 respectively. 98.6% of patients in BC group and 60% of CRC groups were female. This study will be a platform for other cancers to develop CVD risk assessment charts that can cover other cancers. Patients who lie in the high risk category according to the newly developed risk assessment chart, should receive special management and preventive interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Clinical characteristics of COVID-19-infected cancer patients, Isfahan, Iran.
- Author
-
Sharifi, Mehran, Vaseghi, Golnaz, Nasirian, Maryam, Arabzadeh, Saeedeh, Pourhadi, Marjan, Hajiahmadi, Somayeh, Shariati, Laleh, and Javanmard, Shaghayegh
- Subjects
- *
HOSPITALS , *COVID-19 , *AGE distribution , *INTERVIEWING , *QUANTITATIVE research , *LEUKEMIA , *RETROSPECTIVE studies , *ACQUISITION of data , *CANCER patients , *TREATMENT effectiveness , *SOCIOECONOMIC factors , *SEX distribution , *DESCRIPTIVE statistics , *MEDICAL records , *CASE studies , *SOCIODEMOGRAPHIC factors , *ELECTRONIC health records , *BONE marrow , *RESPIRATORY distress syndrome - Abstract
Background: Cancer patients, as a highly vulnerable population, are receiving a great deal of attention in the current crisis of coronavirus 2019 (COVID-19). To date, shreds of evidence are not sufficient to the description of COVID-19 outcomes in patients with cancer. This study was performed to evaluate the demographic and clinical characteristics and subsequent outcomes of COVID-19 in cancer patients. Materials and Methods: A hospital-based study was conducted involving 66 cancer patients with a confirmed diagnosis of COVID-19 from January 15, 2020, to December 21, 2020, in Isfahan, Iran. The clinical information was collected by interview and medical records. The statistical analyses were performed to describe categorical variables as well as mean, standard deviation, median, and the interquartile range for quantitative variables. Results: In our study, 66 cancer patients with confirmed COVID-19 (age: 17–97 years; 50% female) were included. Leukemia and bone marrow cancer with a frequency of 25.7% were the most common types of cancer among them. Cancer patients mostly complained of fever, cough and fatigue, and shortness of breath. Among 76.9% of patients discharged from the hospital with relative recovery, 23% died; the most common cause of death was acute respiratory distress syndrome. Age, gender, and type of cancer did not affect cancer mortality. COVID-19 had no potential effect to increase the risk of side effects of anticancer therapies. Conclusion: The results of our studies revealed that cancer is an important risk factor for the higher rate of mortality in patients with COVID-19. These findings could help physicians for the management, treatment, and supportive care of COVID-19 cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Aflatoxin in pistachio nuts used as ingredients in Gaz sweets produced in Isfahan, Iran.
- Author
-
Jahanmard, Elham, Azarani, Farzaneh, Sharifi, Mehran, and Esfandiari, Zahra
- Subjects
AFLATOXINS ,PISTACHIO ,NUTS ,IMMUNOAFFINITY chromatography ,HIGH performance liquid chromatography ,FLUORESCENCE - Abstract
In Isfahan province of Iran, pistachio and almond are used specifically as ingredients to produce Gaz sweets, which are a typical product of Isfahan and exported to many countries. In this survey, 112 samples were gathered from different corresponding Gaz producers from 2007 to 2012 to evaluate the occurrence of aflatoxins (AF) in these products. Samples were analysed for AFB1, AFB2, AFG1 and AFG2 using immunoaffinity column clean-up (IC) and quantified by high-performance liquid chromatography (HPLC) with fluorescence detection. Among the samples analysed, AFB1 was detected in 13.4% of the samples above the maximum limit (ML) as set in Iran (5 µg/kg). Total AF (AFT) was above the ML in 9.8% of the samples. This study showed that full consideration is equally essential for nuts used as ingredients in special food products such as the Gaz sweets as for nuts for direct human consumption. It suggests a need for modifying the current trend of supervision. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
41. Intestinal Fungal and Parasitic Infections in Kidney Transplant Recipients: A Multi-Center Study.
- Author
-
Naeini, Afsoon Emami, Sharifi, Mehran, Shahidi, Shahrzad, Taheri, Shahram, Seirafian, Shiva, Taheri, Dyana, Tazhibi, Mahdi, Hejazi, Sayyed Hosein, Naini, Pardis Emami, and Harandi, Asghar Amini
- Published
- 2012
- Full Text
- View/download PDF
42. Molecular basis of melatonin protective effects in metastasis: A novel target of melatonin.
- Author
-
Sadoughi, Fatemeh, Maleki Dana, Parisa, Homayoonfal, Mina, Sharifi, Mehran, and Asemi, Zatollah
- Subjects
- *
BREAST , *LUNGS , *CANCER invasiveness , *METASTASIS , *PINEAL gland , *EPITHELIAL-mesenchymal transition , *MELATONIN - Abstract
Currently, cancer is ranked among the top ten causes of death worldwide. Despite the advances made in the field of cancer treatment, 5-year survival rates of various types of cancer are still low due to the recurrence of the disease and/or metastasis. Dissemination of cancer cells, infiltration into the blood vessels, migration to the targeted organs, extravasation, and colonization are the main steps of metastasis. Various factors and signaling pathways are involved in each of these steps. Melatonin (MLT) is a hormone derived from tryptophan and secreted by the pineal gland. This hormone has shown a variety of anti-tumor effects, including anti-oxidative activities, inhibiting the proliferation of tumor cells, inducing apoptosis, and suppressing metastasis. Due to these extensive effects, several studies have been conducted on the applications of MLT in treating different types of cancer. Herein, we review the mechanisms of MLT's effects on the metastasis inhibition of the most lethal types of cancer including the cancer of lung, breast, stomach, kidney, colon, liver, bladder, and pancreas. We discuss how MLT targets different molecules and signaling pathways in each step of the metastasis, such as angiogenesis, remodeling of the extracellular matrix, migration, and epithelial-to-mesenchymal transition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Quantitative Method for the Analysis of Tobacco-Specific Nitrosamines in Cigarette Tobacco and Mainstream Cigarette Smoke by Use of Isotope Dilution Liquid Chromatography Tandem Mass Spectrometry.
- Author
-
Jingcun Wu, Joza, Peter, Sharifi, Mehran, Rickert, William S., and Lauterbach, John H.
- Subjects
- *
QUANTITATIVE research , *NITROSOAMINES , *TOBACCO , *CIGARETTES , *CIGARETTE smoke , *ISOTOPE dilution analysis , *LIQUID chromatography , *MASS spectrometry , *MATRICES (Mathematics) - Abstract
An improved liquid chromatography tandem mass spectrometry (LC-MS/MS) method has been developed for, the determination of tobacco specific nitrosamines (TSNA). It utilizes four stable isotope-labeled internal standards instead of two as reported by others. A separate internal standard for each analyte is required to minimize sample matrix effects on each analyte, which can lead to poor analyte recoveries and decreases in method accuracy and precision if only one or two of the internal standards are used, especially for complex sample matrixes and when no sample cleanup steps are performed as in this study. In addition, two ion-transition pairs (instead of one) are used for each analyte for the confirmation and quantification, further enhancing the method's accuracy and robustness. These improvements have led to a new LC-MS/MS method that is faster, more sensitive, and selective than the traditional methods and more accurate and robust than the published LC-MS/MS methods. The linear range of the method was from 0.2 to 250 ng/mL with a limit of detection of each TSNA varied from 0.02 7 to 0.049 ng/mL. Good correlations between the results obtained by the new method and the traditional method were observed for the samples studied. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
44. The therapeutic effects of berberine for gastrointestinal cancers.
- Author
-
Davoodvandi A, Sadeghi S, Alavi SMA, Alavi SS, Jafari A, Khan H, Aschner M, Mirzaei H, Sharifi M, and Asemi Z
- Subjects
- Humans, Berberine therapeutic use, Berberine pharmacology, Gastrointestinal Neoplasms drug therapy, Antineoplastic Agents therapeutic use
- Abstract
Cancer is one of the most serious human health issues. Drug therapy is the major common way to treat cancer. There is a growing interest in using natural compounds to overcome drug resistance, adverse reactions, and target specificity of certain types of drugs that may affect several targets with fewer side effects and be beneficial against various types of cancer. In this regard, the use of herbal medicines alone or in combination with the main anticancer drugs is commonly available. Berberine (BBR), a nature-driven phytochemical component, is a well-known nutraceutical due to its wide variety of pharmacological activities, including antioxidant, anti-inflammatory, antibacterial, antifungal, antiparasitic, antidiabetic, antihypertensive, and hypolipidemic. In addition, BBR exerts anticancer activities. In present article, we summarized the information available on the therapeutic effects of BBR and its mechanisms on five types of the most prevalent gastrointestinal cancers, including esophageal, gastric, colorectal, hepatocarcinoma, and pancreatic cancers., (© 2023 The Authors. Asia‐Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
45. Performance Challenges in a Newly Established Clean Room at Omid Hospital, Isfahan, Iran: A Descriptive Study.
- Author
-
Vaez M, Sharifi M, Karimi S, and Moghaddas A
- Abstract
Objective: This study aimed to comprehensively assess the challenges faced by a newly established clean room in the oncology center of Omid Hospital, Isfahan, Iran, one of the first of its kind in the country. The research also sought to identify the underlying causes of these challenges and propose potential solutions to address them., Methods: A 6-month cross-sectional study was conducted from December 2021 to May 2022. International guidelines such as British Columbia Cancer Agencies' guideline of hazardous drugs, the National Institute for Occupational Safety and Health guideline for working with hazardous drugs, and United States pharmacopeia related to cleanroom performance were studied, translated, and summarized into a checklist. The staff performance in Omid Hospital's clean room was compared to the data collection form, and all medication errors were documented and analyzed. The study also explained the underlying causes of these challenges and proposed potential solutions., Findings: Among 1005 chemotherapy regimens, 836 errors were detected, stemming from issues such as engineering and construction challenges, lack of human resources and essential equipment, and budgetary constraints., Conclusion: Despite the involvement of a trained oncology clinical pharmacist, Omid Hospital's cleanroom faces significant challenges within the medical and hospital system, leading to non-standard challenges. The study recommends multidisciplinary approaches in the hospital to mitigate these challenges and improve cleanroom performance., Competing Interests: There are no conflicts of interest., (Copyright: © 2024 Journal of Research in Pharmacy Practice.)
- Published
- 2024
- Full Text
- View/download PDF
46. Melatonin as a Promising Agent for Cancer Treatment: Insights into its Effects on the Wnt/beta-catenin Signaling Pathway.
- Author
-
Davoodvandi A, Asemi R, Sharifi M, Reiter RJ, Matini SA, Mirhashemi SM, and Asemi Z
- Subjects
- Humans, Wnt Signaling Pathway, Cell Proliferation, Intercellular Signaling Peptides and Proteins, Apoptosis, beta Catenin metabolism, beta Catenin pharmacology, Cell Line, Tumor, Melatonin pharmacology, Melatonin therapeutic use, Neoplasms pathology
- Abstract
In recent years, substantial advances have been made in cancer treatment modalities. Yet, within the last three decades, neither cancer incidence nor the cancer-induced mortality rate has changed. Available anti-cancer chemotherapeutics possess remarkably restricted effectiveness and often have severe adverse effects. Hence, the identification of novel pharmaceutical agents that do not exhibit these major disadvantages is imperative. Melatonin, an important endogenous molecule synthesized and secreted by the pineal gland, is a promising chemical agent that has been comprehensively assessed over the last decades for its anti-inflammatory and anti-cancer properties. Melatonin is reportedly a significant inhibitor of cancer initiation, progression, and metastasis. The anti-- cancer potential of melatonin is principally mediated by reversing the up-regulated amounts of different transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic agents. Also, melatonin often has signifcant inhibitory effects on cancer cell proliferation through either promoting apoptosis or inducing cell cycle arrest. The current review provides an insight into melatonin-induced effects against various human cancers with a particular focus on the regulation of Wnt/β-catenin signaling pathway., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
47. Modulation of Long Non-coding RNAs and MicroRNAs by Quercetin as a Potential Therapeutical Approach in Cancer: A Comprehensive Review.
- Author
-
Asemi R, Mafi A, Sharifi M, Homayoonfal M, Davoodvandi A, and Asemi Z
- Abstract
Cancer can take years to develop, both at its beginning and during its development. All typical epithelial cancers have a long latency period, sometimes 20 years or more, and if they are clinically detected, distinct genes may include infinite mutations. Long non-coding RNAs (LncRNAs) are a subset of RNAs that regulate many biological processes, including RNA processing, epigenetic control, and signal transduction. Current studies show that lncRNAs, which are dysregulated in cancer, play a significant function in the growth and spread of the illness. LncRNAs have been connected to the overexpression of specific proteins that function in tumors' spread and growth. Moreover, through translational inhibition, microRNAs (miRNAs) regulates gene expression sequence specifically. Apart from that, non-coding RNAs known as miRNAs, with a length of around 22 nucleotides, controls gene expressions in a sequence-specific way either by preventing translation or degrading messenger RNA (mRNA). Quercetin appears to have a significant role in altering miRNA and lncRNA expression, which is linked to variations in the production of oncogenes, tumor suppressors, and proteins produced from cancer. Quercetin may change the earliest epigenetic modifications related to cancer prevention in addition to its usual antioxidant or anti-inflammatory effects. It would be beneficial to have more in-depth information on how Quercetin modulates miRNAs and lncRNAs to use it as a cancer therapeutic strategy. Here, we go through what is known about Quercetin's potential to modulate miRNAs and lncRNAs in various malignancies., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2023
- Full Text
- View/download PDF
48. Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection.
- Author
-
Sadeghi A, Sadeghi S, Peikar MS, Yazdi M, Sharifi M, Ghafel S, Khorvash F, Ataei B, Safavi MR, and Nasri E
- Abstract
Background: With the emergence of the coronavirus disease 2019 (COVID-19) and inability of healthcare systems to control the disease, various therapeutic theories with controversial responses have been proposed. Plasmapheresis was administered as a medication. However, the knowledge of its efficacy and indications is inadequate. This study evaluated the use of plasmapheresis in critically ill patients with cancer., Methods: This randomized clinical trial was conducted on 86 patients with malignancies, including a control group (N=41) and an intervention group (N=45) with severe COVID-19 during 2020-21. Both groups were treated with routine medications for COVID-19 management according to national guidelines, and plasmapheresis was applied to the intervention group. C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase, hemoglobin, and white blood cell, polymorphonuclear, lymphocyte, and platelet levels were measured at admission and at the end of plasmapheresis. Other variables included neutrophil recovery, intensive care unit admission, intubation requirements, length of hospital stay, and hospitalization outcomes., Results: CR P ( P <0.001), D-dimer ( P <0.001), ferritin ( P =0.039), and hemoglobin ( P =0.006) levels were significantly different between the groups after the intervention. Neutrophil recovery was remarkably higher in the case than in the control group ( P <0.001). However, plasmapheresis did not affect the length of hospital stay (P=0.076), which could have significantly increased survival rates ( P <0.001)., Conclusion: Based on the study findings, plasmapheresis led to a significant improvement in laboratory markers and survival rate in patients with severe COVID-19. These findings reinforce the value of plasmapheresis in cancer patients as a critical population suffering from neutropenia and insufficient immune responses.
- Published
- 2023
- Full Text
- View/download PDF
49. Evaluation of clinical outcomes, laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.
- Author
-
Sadeghi S, Peikar M, Sadeghi E, Darakhshandeh A, Ghafel S, Aalinezhad M, Sadeghi A, Sharifi M, and Nasri E
- Abstract
Background: COVID-19 is associated with higher mortality rates in patients with cancer. In this study, we aimed to evaluate the clinical outcomes, and laboratory and imaging data of patients with solid tumor infected with COVID-19 infection., Methods: This is a cross-sectional retrospective study performed in 2020-2022 on 85 patients with a previous diagnosis of solid tumors infected with COVID-19. We included all patients with tumors of solid organs that were diagnosed with COVID-19 infection and required hospitalization those patients previously hospitalized for treatments and were infected with COVID-19 during hospitalization. Demographic data of patients were collected using a checklist. We collected data regarding clinical outcome (discharge, hospitalization or death), duration of hospitalization, requiring ICU admission, duration of hospitalization divided by received drugs and type of tumor and mean survival time. Furthermore, we collected laboratory data from all patients. The radiologic characteristics of patients were also extracted from their data., Results: Breast cancer was the most common solid tumor (34.9%), followed by lung cancer (19.3%). The mortality rate was 24.1% (20 patients). The highest mortality rate in this study was for metastatic intestinal cancer to the lung (100%, one patient), followed by metastatic prostatic cancer to lung (50%, three patients). The highest hospitalization duration was for patients with glioblastoma multiform (GBM) (30 days). The mean survival time among patients with mortality was 19.15±1.80 days. The mean CT severity score of all patients was 27.53±22.90. Patient's most common radiologic sign was air space consolidation (89.1%). The highest CT severity score was found in patients with stomach cancer (46.67±5.77)., Conclusion: The mortality rate in this study was 24.1%. Based on the results of our study and previous research, special care should be provided to patients with solid tumors during the COVID-19 pandemic and in infected cases., Competing Interests: None., (IJBMB Copyright © 2022.)
- Published
- 2022
50. Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial.
- Author
-
Etedali A, Hosseni AK, Derakhshandeh A, Mehrzad V, Sharifi M, and Moghaddas A
- Abstract
Background: Androgen deprivation therapy (ADT) has been considered as a mainstay of treatment for advanced prostate cancer. Considering ADT for cancer patients is accompanied with many side effects, such as behavioral and neurologic side effects that adversely affect the quality of life., Objectives: This study aimed to evaluate the effects of melatonin administration on sleep problems and mood changes induced by ADT in prostate cancer patients., Methods: The randomized, double-blind, placebo-controlled trial was designed in the oncology-hematology outpatient clinic of Omid Hospital, Isfahan, Iran. After screening by the hospital anxiety and depression scale (HADS), patients were divided into either an intervention group receiving 6 mg melatonin daily for four weeks or an identical placebo. After that, patients were evaluated by the Pittsburgh sleep quality index (PSQI), the Hamilton Anxiety Rating Scale (HAM-A), and Beck Depression Inventory (BDI) questionnaires at baseline and after 4-week follow-ups., Results: Forty-three patients, including 21 and 22 patients in melatonin and placebo groups, respectively completed follow-ups period. Melatonin administration significantly improved PSQI scores in four domains of sleep quality, sleep latency, sleep efficacy, and daytime dysfunction. After 4-week melatonin supplementation, the severity of depression and anxiety assessed by BDI and HAM-A questionnaires, respectively, decreased non-statistically significant in both melatonin and placebo groups., Conclusions: In our study, melatonin supplementation ameliorated ADT-induced sleep problems in patients with prostate cancers; however, for more conclusive results, further future large and well-designed clinical studies is warranted., Competing Interests: Conflict of Interests: The corresponding author has been working as a faculty member at Isfahan University of Medical Sciences, Isfahan, Iran. She received financial support (ID: Grant number:198253) from Isfahan University of Medical Sciences, Isfahan, Iran, and financially supported the whole parts of the study protocol, including company and patients' payment, statistical consultation fee, etc. There is no unpaid membership in this study. None of the authors is an editorial board member; however, they may invite as a reviewer from this journal., (Copyright © 2022, Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.